{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:58:41Z","timestamp":1789657121825,"version":"4.0.1"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Among hematological malignancies, multiple myeloma (MM) represents the leading indication of autologous hematopoietic stem cell transplantation (auto-HCT). Auto-HCT is predominantly performed with peripheral blood stem cells (PBSCs), and the mobilization and collection of PBSCs are essential steps for auto-HCT. Despite the improved success of conventional methods with the incorporation of novel agents for PBSC mobilization in MM, mobilization failure is still a concern. The current review comprehensively summarizes various mobilization strategies for mobilizing PBSCs in MM patients and the evolution of these strategies over time. Moreover, existing evidence substantiates that the mobilization regimen used may be an important determinant of graft content. However, limited data are available on the effects of graft characteristics in patient outcomes other than hematopoietic engraftment. In this review, we discussed the effect of graft characteristics on clinical outcomes, mobilization failure, factors predictive of poor mobilization, and potential mobilization regimens for such patients.<\/jats:p>","DOI":"10.1007\/s00277-023-05170-0","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T18:02:28Z","timestamp":1679508148000},"page":"995-1009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments"],"prefix":"10.1007","volume":"102","author":[{"given":"Xiaolei","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"5170_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97:1086\u20131107. https:\/\/doi.org\/10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"5170_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","volume":"9","author":"R Al Hamed","year":"2019","unstructured":"Al Hamed R, Bazarbachi AH, Malard F et al (2019) Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J 9:44. https:\/\/doi.org\/10.1038\/s41408-019-0205-9","journal-title":"Blood Cancer J"},{"key":"5170_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1200\/JOP.19.00335","volume":"16","author":"RD Parrondo","year":"2020","unstructured":"Parrondo RD, Ailawadhi S, Sher T et al (2020) Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies. JCO Oncol Pract 16:56\u201366. https:\/\/doi.org\/10.1200\/JOP.19.00335","journal-title":"JCO Oncol Pract"},{"key":"5170_CR4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","volume":"56","author":"JR Passweg","year":"2021","unstructured":"Passweg JR, Baldomero H, Chabannon C et al (2021) Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant 56:1651\u20131664. https:\/\/doi.org\/10.1038\/s41409-021-01227-8","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.blre.2014.01.001","volume":"28","author":"RK Hopman","year":"2014","unstructured":"Hopman RK, DiPersio JF (2014) Advances in stem cell mobilization. Blood Rev 28:31\u201340. https:\/\/doi.org\/10.1016\/j.blre.2014.01.001","journal-title":"Blood Rev"},{"key":"5170_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/bmt.2008.410","volume":"43","author":"W Bensinger","year":"2009","unstructured":"Bensinger W, DiPersio JF, McCarty JM (2009) Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 43:181\u2013195. https:\/\/doi.org\/10.1038\/bmt.2008.410","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR7","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1111\/trf.13574","volume":"56","author":"J Valtola","year":"2016","unstructured":"Valtola J, Silvennoinen R, Ropponen A et al (2016) Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. Transfusion (Paris) 56:1394\u20131401. https:\/\/doi.org\/10.1111\/trf.13574","journal-title":"Transfusion (Paris)"},{"key":"5170_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/bmt.2010.320","volume":"46","author":"E Jantunen","year":"2011","unstructured":"Jantunen E, Fruehauf S (2011) Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. Bone Marrow Transplant 46:627\u2013635. https:\/\/doi.org\/10.1038\/bmt.2010.320","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR9","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/leu.2009.127","volume":"23","author":"S Giralt","year":"2009","unstructured":"Giralt S, Stadtmauer EA, Harousseau JL et al (2009) International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23:1904\u20131912. https:\/\/doi.org\/10.1038\/leu.2009.127","journal-title":"Leukemia"},{"key":"5170_CR10","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3906\/sag-2001-173","volume":"50","author":"E Alada\u011f Karakulak","year":"2020","unstructured":"Alada\u011f Karakulak E, Demiro\u011flu H, B\u00fcy\u00fcka\u015fik Y et al (2020) CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. Turk J Med Sci 50:1851\u20131856. https:\/\/doi.org\/10.3906\/sag-2001-173","journal-title":"Turk J Med Sci"},{"key":"5170_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2895.x","volume":"78","author":"J Klaus","year":"2007","unstructured":"Klaus J, Herrmann D, Breitkreutz I et al (2007) Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 78:21\u201328. https:\/\/doi.org\/10.1111\/j.0902-4441.2006.t01-1-EJH2895.x","journal-title":"Eur J Haematol"},{"key":"5170_CR12","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1365-2141.2004.04837.x","volume":"124","author":"AA Toor","year":"2004","unstructured":"Toor AA, Ayers J, Strupeck J et al (2004) Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma: Bu-Cy in multiple myeloma. Br J Haematol 124:769\u2013776. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.04837.x","journal-title":"Br J Haematol"},{"key":"5170_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1600-0609.2004.00297.x","volume":"73","author":"A Wahlin","year":"2004","unstructured":"Wahlin A, Eriksson M, Hultdin M (2004) Relation between harvest success and outcome after autologous peripheral blood stem cell transplantation in multiple myeloma: Harvest and outcome in myeloma. Eur J Haematol 73:263\u2013268. https:\/\/doi.org\/10.1111\/j.1600-0609.2004.00297.x","journal-title":"Eur J Haematol"},{"key":"5170_CR14","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1182\/blood-2021-151862","volume":"138","author":"E Lebel","year":"2021","unstructured":"Lebel E, Lajkosz K, Masih-Khan E et al (2021) Supermobilizers with high CD34 + cell collection for autologous transplant and impact on survival outcomes in multiple myeloma. Blood 138:1837. https:\/\/doi.org\/10.1182\/blood-2021-151862","journal-title":"Blood"},{"key":"5170_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bmt.1701368","volume":"22","author":"B Millar","year":"1998","unstructured":"Millar B, Millar J, Shepherd V et al (1998) The importance of CD34+\/CD33\u2212 cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Bone Marrow Transplant 22:469\u2013475. https:\/\/doi.org\/10.1038\/sj.bmt.1701368","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR16","first-page":"489","volume":"83","author":"A Sampol Mayol","year":"1998","unstructured":"Sampol Mayol A, Besalduch Vital J, Galm\u00e9s Llodr\u00e1 A et al (1998) CD34+ cell dose and CD33-subsets: collection and engraftment kinetics in autologous peripheral blood stem cells transplantation. Haematologica 83:489\u2013495","journal-title":"Haematologica"},{"key":"5170_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/stem.5530160814","volume":"16","author":"Ph H\u00e9non","year":"2009","unstructured":"H\u00e9non Ph, Sovalat H, Wunder E et al (2009) Role of the CD34+38\u2212 cells in posttransplant hematopoietic recovery. Stem Cells 16:113\u2013122. https:\/\/doi.org\/10.1002\/stem.5530160814","journal-title":"Stem Cells"},{"key":"5170_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14653240600847241","volume":"8","author":"AC Zubair","year":"2006","unstructured":"Zubair AC, Kao G, Daley H et al (2006) CD34(+) CD38(-) and CD34(+) HLA-DR(-) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. Cytotherapy 8:399\u2013407. https:\/\/doi.org\/10.1080\/14653240600847241","journal-title":"Cytotherapy"},{"key":"5170_CR19","doi-asserted-by":"publisher","first-page":"651288","DOI":"10.3389\/fimmu.2021.651288","volume":"12","author":"SA Minnie","year":"2021","unstructured":"Minnie SA, Hill GR (2021) Autologous stem cell transplantation for myeloma: cytoreduction or an immunotherapy? Front Immunol 12:651288. https:\/\/doi.org\/10.3389\/fimmu.2021.651288","journal-title":"Front Immunol"},{"key":"5170_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bbmt.2007.08.051","volume":"14","author":"DK Hiwase","year":"2008","unstructured":"Hiwase DK, Hiwase S, Bailey M et al (2008) Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 14:116\u2013124. https:\/\/doi.org\/10.1016\/j.bbmt.2007.08.051","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR21","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.bbmt.2016.01.024","volume":"22","author":"LF Porrata","year":"2016","unstructured":"Porrata LF, Burgstaler EA, Winters JL et al (2016) Immunologic autograft engineering and survival in non-Hodgkin lymphoma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 22:1017\u20131023. https:\/\/doi.org\/10.1016\/j.bbmt.2016.01.024","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR22","doi-asserted-by":"publisher","first-page":"769.e1","DOI":"10.1016\/j.jtct.2021.05.026","volume":"27","author":"LF Porrata","year":"2021","unstructured":"Porrata LF, Burgstaler EA, Winters JL et al (2021) Infused autograft absolute lymphocyte count predicts superior survival in diffuse large B cell lymphoma patients post-autologous peripheral blood hematopoietic stem cell transplantation: a matched case-control study. Transplant Cell Ther 27:769.e1-769.e8. https:\/\/doi.org\/10.1016\/j.jtct.2021.05.026","journal-title":"Transplant Cell Ther"},{"key":"5170_CR23","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1182\/blood-2021-144345","volume":"138","author":"LF Porrata","year":"2021","unstructured":"Porrata LF, Inwards DJ, Ansell SM et al (2021) Autograft-absolute lymphocyte count infusion predicts survival in double\/triple hit lymphomas post-autologous peripheral blood hematopoietic stem cell transplantation. Blood 138:1836. https:\/\/doi.org\/10.1182\/blood-2021-144345","journal-title":"Blood"},{"key":"5170_CR24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1365-2141.2008.07123.x","volume":"141","author":"H Ege","year":"2008","unstructured":"Ege H, Gertz MA, Markovic SN et al (2008) Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol 141:792\u2013798. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07123.x","journal-title":"Br J Haematol"},{"key":"5170_CR25","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/sj.leu.2403341","volume":"18","author":"LF Porrata","year":"2004","unstructured":"Porrata LF, Gertz MA, Geyer SM et al (2004) The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 18:1085\u20131092. https:\/\/doi.org\/10.1038\/sj.leu.2403341","journal-title":"Leukemia"},{"key":"5170_CR26","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3109\/10428194.2014.1003057","volume":"56","author":"VH Jimenez-Zepeda","year":"2015","unstructured":"Jimenez-Zepeda VH, Reece DE, Trudel S et al (2015) Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant. Leuk Lymphoma 56:2668\u20132673. https:\/\/doi.org\/10.3109\/10428194.2014.1003057","journal-title":"Leuk Lymphoma"},{"key":"5170_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.clml.2014.10.002","volume":"15","author":"V Narwani","year":"2015","unstructured":"Narwani V, Gabriel J, Boyd K, Chevassut T (2015) Absolute lymphocyte count at day 29 of treatment is a powerful predictor of outcome in multiple myeloma. Clin Lymphoma Myeloma Leuk 15:222\u2013226. https:\/\/doi.org\/10.1016\/j.clml.2014.10.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5170_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/ajh.21314","volume":"84","author":"EH Atta","year":"2009","unstructured":"Atta EH, de Azevedo AM, Maiolino A et al (2009) High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation. Am J Hematol 84:21\u201328. https:\/\/doi.org\/10.1002\/ajh.21314","journal-title":"Am J Hematol"},{"key":"5170_CR29","first-page":"240","volume":"30","author":"R Schmidmaier","year":"2008","unstructured":"Schmidmaier R, Oversohl N, Schnabel B et al (2008) Helper T cells (CD3 + \/CD4 + ) within the autologous peripheral blood stem cell graft positively correlate with event free survival of multiple myeloma patients. Exp Oncol 30:240\u2013243","journal-title":"Exp Oncol"},{"key":"5170_CR30","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1182\/blood-2021-151439","volume":"138","author":"M Kaddoura","year":"2021","unstructured":"Kaddoura M, Gertz MA, Dingli D et al (2021) Prognostic impact of CD3 count in apheresis collection in multiple myeloma patients undergoing autologous stem cell transplant. Blood 138:3774. https:\/\/doi.org\/10.1182\/blood-2021-151439","journal-title":"Blood"},{"key":"5170_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3109\/14653249.2012.655421","volume":"14","author":"S-E Lee","year":"2012","unstructured":"Lee S-E, Yahng S-A, Cho B-S et al (2012) Lymphocyte subset analysis for the assessment of treatment-related complications after autologous stem cell transplantation in multiple myeloma. Cytotherapy 14:505\u2013512. https:\/\/doi.org\/10.3109\/14653249.2012.655421","journal-title":"Cytotherapy"},{"key":"5170_CR32","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.bbmt.2014.03.007","volume":"20","author":"J Rueff","year":"2014","unstructured":"Rueff J, Medinger M, Heim D et al (2014) Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 20:896\u2013899. https:\/\/doi.org\/10.1016\/j.bbmt.2014.03.007","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR33","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1182\/blood-2021-148454","volume":"138","author":"LF Porrata","year":"2021","unstructured":"Porrata LF, Inwards DJ, Ansell SM et al (2021) Immunologic autograft engineering: 13 years follow-up. Blood 138:3936. https:\/\/doi.org\/10.1182\/blood-2021-148454","journal-title":"Blood"},{"key":"5170_CR34","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/trf.16424","volume":"61","author":"A Turunen","year":"2021","unstructured":"Turunen A, Silvennoinen R, Partanen A et al (2021) Autograft cellular composition and outcome in myeloma patients: results of the prospective multicenter GOA study. Transfusion (Paris) 61:1830\u20131844. https:\/\/doi.org\/10.1111\/trf.16424","journal-title":"Transfusion (Paris)"},{"key":"5170_CR35","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/sj.bmt.1705183","volume":"36","author":"R Dean","year":"2005","unstructured":"Dean R, Masci P, Pohlman B et al (2005) Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival. Bone Marrow Transplant 36:1049\u20131052. https:\/\/doi.org\/10.1038\/sj.bmt.1705183","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR36","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00432-004-0635-y","volume":"131","author":"W Vogel","year":"2005","unstructured":"Vogel W, Kopp H-G, Kanz L, Einsele H (2005) Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol 131:214\u2013218. https:\/\/doi.org\/10.1007\/s00432-004-0635-y","journal-title":"J Cancer Res Clin Oncol"},{"key":"5170_CR37","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.3390\/cancers13164047","volume":"13","author":"IV Kostopoulos","year":"2021","unstructured":"Kostopoulos IV, Eleutherakis-Papaiakovou E, Rousakis P et al (2021) Aberrant plasma cell contamination of peripheral blood stem cell autografts, assessed by next-generation flow cytometry, is a negative predictor for deep response post autologous transplantation in multiple myeloma; a prospective study in 199 patients. Cancers 13:4047. https:\/\/doi.org\/10.3390\/cancers13164047","journal-title":"Cancers"},{"key":"5170_CR38","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.bbmt.2020.04.011","volume":"26","author":"S Bal","year":"2020","unstructured":"Bal S, Landau HJ, Shah GL et al (2020) Stem cell mobilization and autograft minimal residual disease negativity with novel induction regimens in multiple myeloma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 26:1394\u20131401. https:\/\/doi.org\/10.1016\/j.bbmt.2020.04.011","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR39","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00432-008-0499-7","volume":"135","author":"HG Kopp","year":"2009","unstructured":"Kopp HG, Yildirim S, Weisel KC et al (2009) Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma. J Cancer Res Clin Oncol 135:637\u2013642. https:\/\/doi.org\/10.1007\/s00432-008-0499-7","journal-title":"J Cancer Res Clin Oncol"},{"key":"5170_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/bmt.2008.318","volume":"43","author":"J Ho","year":"2009","unstructured":"Ho J, Yang L, Banihashemi B et al (2009) Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant 43:223\u2013228. https:\/\/doi.org\/10.1038\/bmt.2008.318","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR41","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"5170_CR42","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","volume":"112","author":"B Paiva","year":"2008","unstructured":"Paiva B, Vidriales M-B, Cerver\u00f3 J et al (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112:4017\u20134023. https:\/\/doi.org\/10.1182\/blood-2008-05-159624","journal-title":"Blood"},{"key":"5170_CR43","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.bbmt.2010.10.018","volume":"17","author":"JF DiPersio","year":"2011","unstructured":"DiPersio JF, Ho AD, Hanrahan J et al (2011) Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 17:943\u2013955. https:\/\/doi.org\/10.1016\/j.bbmt.2010.10.018","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR44","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/s41409-021-01300-2","volume":"56","author":"MJ Rees","year":"2021","unstructured":"Rees MJ, Mollee P, Ng JY et al (2021) The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. Bone Marrow Transplant 56:2152\u20132159. https:\/\/doi.org\/10.1038\/s41409-021-01300-2","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR45","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3109\/14653240903121245","volume":"11","author":"S Fruehauf","year":"2009","unstructured":"Fruehauf S, Veldwijk MR, Seeger T et al (2009) A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 11:992\u20131001. https:\/\/doi.org\/10.3109\/14653240903121245","journal-title":"Cytotherapy"},{"key":"5170_CR46","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","volume":"20","author":"HK Duong","year":"2014","unstructured":"Duong HK, Savani BN, Copelan E et al (2014) Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 20:1262\u20131273. https:\/\/doi.org\/10.1016\/j.bbmt.2014.05.003","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR47","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Micallef IN, Stiff PJ et al (2009) Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 27:4767\u20134773. https:\/\/doi.org\/10.1200\/JCO.2008.20.7209","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5170_CR48","doi-asserted-by":"publisher","first-page":"250","DOI":"10.5500\/wjt.v7.i5.250","volume":"7","author":"WD Wallis","year":"2017","unstructured":"Wallis WD, Qazilbash MH (2017) Peripheral blood stem cell mobilization in multiple myeloma: growth factors or chemotherapy? World J Transplant 7:250\u2013259. https:\/\/doi.org\/10.5500\/wjt.v7.i5.250","journal-title":"World J Transplant"},{"key":"5170_CR49","doi-asserted-by":"publisher","unstructured":"Elayan MM, Horowitz JG, Magraner JM et al (2015) Tbo-filgrastim versus filgrastim during mobilization and neutrophil engraftment for autologous stem cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 21:. https:\/\/doi.org\/10.1016\/j.bbmt.2015.05.024","DOI":"10.1016\/j.bbmt.2015.05.024"},{"key":"5170_CR50","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3324\/haematol.13204","volume":"93","author":"G Tricot","year":"2008","unstructured":"Tricot G, Barlogie B, Zangari M et al (2008) Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica 93:1739\u20131742. https:\/\/doi.org\/10.3324\/haematol.13204","journal-title":"Haematologica"},{"key":"5170_CR51","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/bmt.2014.297","volume":"50","author":"MG Kim","year":"2015","unstructured":"Kim MG, Han N, Lee E-K, Kim T (2015) Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone Marrow Transplant 50:523\u2013530. https:\/\/doi.org\/10.1038\/bmt.2014.297","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR52","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s12185-018-2408-4","volume":"107","author":"A Tanimura","year":"2018","unstructured":"Tanimura A, Hirai R, Nakamura M et al (2018) Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone. Int J Hematol 107:559\u2013567. https:\/\/doi.org\/10.1007\/s12185-018-2408-4","journal-title":"Int J Hematol"},{"key":"5170_CR53","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1182\/blood.V126.23.1898.1898","volume":"126","author":"RS Whitmill","year":"2015","unstructured":"Whitmill RS (2015) A retrospective single center comparison of cyclophosphamide plus G-CSF versus G-CSF alone for peripheral blood stem cell (PBSC) mobilisation following first line therapy in patients with multiple myeloma. Blood 126:1898","journal-title":"Blood"},{"key":"5170_CR54","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00277-020-04376-w","volume":"100","author":"L Wang","year":"2021","unstructured":"Wang L, Xiang H, Yan Y et al (2021) Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis. Ann Hematol 100:563\u2013573. https:\/\/doi.org\/10.1007\/s00277-020-04376-w","journal-title":"Ann Hematol"},{"key":"5170_CR55","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1182\/blood.V95.5.1588.005k38_1588_1593","volume":"95","author":"A Krishnan","year":"2000","unstructured":"Krishnan A, Bhatia S, Slovak ML et al (2000) Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 95:1588\u20131593","journal-title":"Blood"},{"key":"5170_CR56","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41409-018-0396-x","volume":"54","author":"T Jelinek","year":"2019","unstructured":"Jelinek T, Adamusova L, Popkova T et al (2019) Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma. Bone Marrow Transplant 54:1107\u20131114. https:\/\/doi.org\/10.1038\/s41409-018-0396-x","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR57","doi-asserted-by":"publisher","first-page":"825550","DOI":"10.3389\/fonc.2022.825550","volume":"12","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Li X, Liu Y et al (2022) High efficacy of stem cell mobilization with etoposide+cytarabine plus G-CSF in patients with multiple myeloma. Front Oncol 12:825550. https:\/\/doi.org\/10.3389\/fonc.2022.825550","journal-title":"Front Oncol"},{"key":"5170_CR58","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2003-02-0663","volume":"102","author":"WC Liles","year":"2003","unstructured":"Liles WC, Broxmeyer HE, Rodger E et al (2003) Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102:2728\u20132730. https:\/\/doi.org\/10.1182\/blood-2003-02-0663","journal-title":"Blood"},{"key":"5170_CR59","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/jca.21496","volume":"32","author":"N Worel","year":"2017","unstructured":"Worel N, Fritsch G, Agis H et al (2017) Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. J Clin Apheresis 32:224\u2013234. https:\/\/doi.org\/10.1002\/jca.21496","journal-title":"J Clin Apheresis"},{"key":"5170_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-02278-5","volume-title":"The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies","author":"E Carreras","year":"2019","unstructured":"Carreras E, Dufour C, Mohty M, Kr\u00f6ger N (2019) The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies, 7th edn. Springer, Cham (CH)","edition":"7"},{"key":"5170_CR61","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jca.21563","volume":"33","author":"KW Douglas","year":"2018","unstructured":"Douglas KW, Gilleece M, Hayden P et al (2018) UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. J Clin Apheresis 33:46\u201359. https:\/\/doi.org\/10.1002\/jca.21563","journal-title":"J Clin Apheresis"},{"key":"5170_CR62","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.bbmt.2019.11.024","volume":"26","author":"EE Shah","year":"2020","unstructured":"Shah EE, Young RP, Wong SW et al (2020) Impact of plerixafor use at different peripheral blood CD34+ thresholds on autologous stem cell collection in patients with multiple myeloma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 26:876\u2013883. https:\/\/doi.org\/10.1016\/j.bbmt.2019.11.024","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR63","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1111\/trf.12102","volume":"53","author":"YC Tanhehco","year":"2013","unstructured":"Tanhehco YC, Vogl DT, Stadtmauer EA, O\u2019Doherty U (2013) The evolving role of plerixafor in hematopoietic progenitor cell mobilization. Transfusion (Paris) 53:2314\u20132326. https:\/\/doi.org\/10.1111\/trf.12102","journal-title":"Transfusion (Paris)"},{"key":"5170_CR64","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1080\/10428194.2016.1271946","volume":"58","author":"C Greil","year":"2017","unstructured":"Greil C, Kiote-Schmidt C, Fink G et al (2017) Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers. Leuk Lymphoma 58:1849\u20131858. https:\/\/doi.org\/10.1080\/10428194.2016.1271946","journal-title":"Leuk Lymphoma"},{"key":"5170_CR65","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1080\/10428194.2017.1393673","volume":"59","author":"C Greil","year":"2018","unstructured":"Greil C, Ihorst G, Kiote-Schmidt C et al (2018) Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule. Leuk Lymphoma 59:1722\u20131725. https:\/\/doi.org\/10.1080\/10428194.2017.1393673","journal-title":"Leuk Lymphoma"},{"key":"5170_CR66","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/bmt.2015.322","volume":"51","author":"S Afifi","year":"2016","unstructured":"Afifi S, Adel NG, Devlin S et al (2016) Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transplant 51:546\u2013552. https:\/\/doi.org\/10.1038\/bmt.2015.322","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR67","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1016\/j.bbmt.2009.12.160","volume":"16","author":"CJ Campen","year":"2010","unstructured":"Campen CJ, Armstrong EP, Christian JA et al (2010) Comparative cost-effectiveness of plerixafor plus granulocyte-colony stimulating factor versus cyclophosphamide plus granulocyte-colony stimulating for autologous peripheral blood stem cell mobilization in patients with non-Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant 16:S206. https:\/\/doi.org\/10.1016\/j.bbmt.2009.12.160","journal-title":"Biol Blood Marrow Transplant"},{"key":"5170_CR68","doi-asserted-by":"publisher","unstructured":"Veltri LW, Cumpston A, Shillingburg A et al (2014) Cost and efficacy of upfront plerixafor versus a \u201cjust-in-time\u201d (JIT) approach in hematopoietic progenitor cell (HPC) mobilization. 124:1127. https:\/\/doi.org\/10.1182\/blood.V124.21.1127.1127","DOI":"10.1182\/blood.V124.21.1127.1127"},{"key":"5170_CR69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/trf.13868","volume":"57","author":"S Yuan","year":"2017","unstructured":"Yuan S, Wang S (2017) How do we mobilize and collect autologous peripheral blood stem cells? Transfusion (Paris) 57:13\u201323. https:\/\/doi.org\/10.1111\/trf.13868","journal-title":"Transfusion (Paris)"},{"key":"5170_CR70","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt S, Costa L, Schriber J et al (2014) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 20:295\u2013308. https:\/\/doi.org\/10.1016\/j.bbmt.2013.10.013","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR71","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1537-2995.2006.00774.x","volume":"46","author":"KR Meehan","year":"2006","unstructured":"Meehan KR, Hill JM, Patchett L et al (2006) Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization. Transfusion (Paris) 46:523\u2013529. https:\/\/doi.org\/10.1111\/j.1537-2995.2006.00774.x","journal-title":"Transfusion (Paris)"},{"key":"5170_CR72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/bmt.2014.196","volume":"50","author":"I S\u00e1nchez-Ortega","year":"2015","unstructured":"S\u00e1nchez-Ortega I, Querol S, Encuentra M et al (2015) Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. Bone Marrow Transplant 50:34\u201339. https:\/\/doi.org\/10.1038\/bmt.2014.196","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR73","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/bmt.2017.80","volume":"52","author":"M Mohty","year":"2017","unstructured":"Mohty M, Drillat P, Grouin J-M et al (2017) Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function. Bone Marrow Transplant 52:1049\u20131050. https:\/\/doi.org\/10.1038\/bmt.2017.80","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR74","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","volume":"14","author":"I Pusic","year":"2008","unstructured":"Pusic I, Jiang SY, Landua S et al (2008) Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 14:1045\u20131056. https:\/\/doi.org\/10.1016\/j.bbmt.2008.07.004","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR75","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/bmt.2009.130","volume":"45","author":"G Tricot","year":"2010","unstructured":"Tricot G, Cottler-Fox MH, Calandra G (2010) Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 45:63\u201368. https:\/\/doi.org\/10.1038\/bmt.2009.130","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR76","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.transci.2012.06.008","volume":"47","author":"N Piccirillo","year":"2012","unstructured":"Piccirillo N, Vacca M, Lanti A et al (2012) Poor mobilizer: a retrospective study on proven and predicted incidence according to GITMO criteria. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 47:217\u2013221. https:\/\/doi.org\/10.1016\/j.transci.2012.06.008","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"5170_CR77","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.transci.2016.11.005","volume":"56","author":"P Ataca Atilla","year":"2017","unstructured":"Ataca Atilla P, Bakanay Ozturk SM, Demirer T (2017) How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation? Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 56:190\u2013198. https:\/\/doi.org\/10.1016\/j.transci.2016.11.005","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"5170_CR78","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","volume":"16","author":"P Wuchter","year":"2010","unstructured":"Wuchter P, Ran D, Bruckner T et al (2010) Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 16:490\u2013499. https:\/\/doi.org\/10.1016\/j.bbmt.2009.11.012","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR79","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","volume":"114","author":"S Kumar","year":"2009","unstructured":"Kumar S, Giralt S, Stadtmauer EA et al (2009) Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114:1729\u20131735. https:\/\/doi.org\/10.1182\/blood-2009-04-205013","journal-title":"Blood"},{"key":"5170_CR80","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/leu.2012.323","volume":"27","author":"S Li","year":"2013","unstructured":"Li S, Fu J, Ma H et al (2013) Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization. Leukemia 27:1407\u20131411. https:\/\/doi.org\/10.1038\/leu.2012.323","journal-title":"Leukemia"},{"key":"5170_CR81","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s12288-019-01135-4","volume":"35","author":"K Mishra","year":"2019","unstructured":"Mishra K, Jandial A, Sandal R et al (2019) Poor mobilisation after daratumumab based combination chemotherapy in patients of newly diagnosed multiple myeloma. Indian J Hematol Blood Transfus Off J Indian Soc Hematol Blood Transfus 35:584\u2013586. https:\/\/doi.org\/10.1007\/s12288-019-01135-4","journal-title":"Indian J Hematol Blood Transfus Off J Indian Soc Hematol Blood Transfus"},{"key":"5170_CR82","doi-asserted-by":"crossref","unstructured":"Eleutherakis Papaiakovou E (2021) Impact of daratumumab-containing induction on stem cell mobilization and collection, engraftment and hospitalization parameters among multiple myeloma patients undergoing autologous stem cell transplantation. ASH","DOI":"10.1182\/blood-2021-149499"},{"key":"5170_CR83","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/trf.12813","volume":"55","author":"J Cheng","year":"2015","unstructured":"Cheng J, Schmitt M, Wuchter P et al (2015) Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion (Paris) 55:275\u2013283. https:\/\/doi.org\/10.1111\/trf.12813","journal-title":"Transfusion (Paris)"},{"key":"5170_CR84","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1537-2995.2011.03349.x","volume":"52","author":"E Jantunen","year":"2012","unstructured":"Jantunen E, Lemoli RM (2012) Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion (Paris) 52:906\u2013914. https:\/\/doi.org\/10.1111\/j.1537-2995.2011.03349.x","journal-title":"Transfusion (Paris)"},{"key":"5170_CR85","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1182\/blood.V118.21.4060.4060","volume":"118","author":"J Shapiro","year":"2011","unstructured":"Shapiro J, Perkins J, Bookout R et al (2011) Evaluation of a risk-based algorithm for the utilization of plerixafor as primary mobilization of CD34+ cells in autologous hematopoietic cell transplant candidates. Blood 118:4060. https:\/\/doi.org\/10.1182\/blood.V118.21.4060.4060","journal-title":"Blood"},{"key":"5170_CR86","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.bbmt.2017.11.014","volume":"24","author":"SR Jaiswal","year":"2018","unstructured":"Jaiswal SR, Bhakuni P, Joy A et al (2018) Impact of single-dose plerixafor as an adjunct to granulocyte colony-stimulating factor-based peripheral blood stem cell mobilization on the graft composition and outcome for T cell-replete haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide: a comparative study. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 24:542\u2013548. https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.014","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR87","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/10428194.2016.1239261","volume":"58","author":"A Ogunniyi","year":"2017","unstructured":"Ogunniyi A, Rodriguez M, Devlin S et al (2017) Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency. Leuk Lymphoma 58:1123\u20131129. https:\/\/doi.org\/10.1080\/10428194.2016.1239261","journal-title":"Leuk Lymphoma"},{"key":"5170_CR88","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/bmt.2010.128","volume":"46","author":"A D\u2019Addio","year":"2011","unstructured":"D\u2019Addio A, Curti A, Worel N et al (2011) The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 46:356\u2013363. https:\/\/doi.org\/10.1038\/bmt.2010.128","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR89","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/bmt.2009.119","volume":"45","author":"MJ Dugan","year":"2010","unstructured":"Dugan MJ, Maziarz RT, Bensinger WI et al (2010) Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin\u2019s lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 45:39\u201347. https:\/\/doi.org\/10.1038\/bmt.2009.119","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR90","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.transci.2011.01.005","volume":"44","author":"I Bojanic","year":"2011","unstructured":"Bojanic I, Dubravcic K, Batinic D et al (2011) Large volume leukapheresis: efficacy and safety of processing patient\u2019s total blood volume six times. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 44:139\u2013147. https:\/\/doi.org\/10.1016\/j.transci.2011.01.005","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"5170_CR91","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.transci.2004.10.018","volume":"32","author":"Z Gasov\u00e1","year":"2005","unstructured":"Gasov\u00e1 Z, Marinov I, Vodv\u00e1rkov\u00e1 S et al (2005) PBPC collection techniques: standard versus large volume leukapheresis (LVL) in donors and in patients. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 32:167\u2013176. https:\/\/doi.org\/10.1016\/j.transci.2004.10.018","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"5170_CR92","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2450\/2016.0151-15","volume":"15","author":"I Bojanic","year":"2017","unstructured":"Bojanic I, Mazic S, Rajic L et al (2017) Large volume leukapheresis is efficient and safe even in small children up to 15 kg body weight. Blood Transfus Trasfus Sangue 15:85\u201392. https:\/\/doi.org\/10.2450\/2016.0151-15","journal-title":"Blood Transfus Trasfus Sangue"},{"key":"5170_CR93","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1046\/j.1365-2141.2002.03264.x","volume":"116","author":"T Demirer","year":"2002","unstructured":"Demirer T, Ayli M, Ozcan M et al (2002) Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 116:468\u2013474. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03264.x","journal-title":"Br J Haematol"},{"key":"5170_CR94","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/bmt.2009.161","volume":"44","author":"T Ozcelik","year":"2009","unstructured":"Ozcelik T, Topcuoglu P, Beksac M et al (2009) Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF. Bone Marrow Transplant 44:779\u2013783. https:\/\/doi.org\/10.1038\/bmt.2009.161","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR95","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","volume":"41","author":"G Calandra","year":"2008","unstructured":"Calandra G, McCarty J, McGuirk J et al (2008) AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin\u2019s lymphoma, Hodgkin\u2019s disease and multiple myeloma patients previously failing mobilization with chemotherapy and\/or cytokine treatment: compassionate use data. Bone Marrow Transplant 41:331\u2013338. https:\/\/doi.org\/10.1038\/sj.bmt.1705908","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR96","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/bmt.2010.54","volume":"46","author":"RF Duarte","year":"2011","unstructured":"Duarte RF, Shaw BE, Mar\u00edn P et al (2011) Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 46:52\u201358. https:\/\/doi.org\/10.1038\/bmt.2010.54","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR97","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1515\/raon-2016-0028","volume":"50","author":"M Skerget","year":"2016","unstructured":"Skerget M, Skopec B, Zontar D, Cernelc P (2016) Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Radiol Oncol 50:402\u2013408. https:\/\/doi.org\/10.1515\/raon-2016-0028","journal-title":"Radiol Oncol"},{"key":"5170_CR98","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood.V106.11.1174.1174","volume":"106","author":"LF Porrata","year":"2005","unstructured":"Porrata LF, Hayman SR, Gertz MA et al (2005) The role of stem cell mobilization regimen on lymphocyte collection yield and survival after autologous hematopoietic stem cell transplantation in multiple myeloma. Blood 106:1174\u20131174. https:\/\/doi.org\/10.1182\/blood.V106.11.1174.1174","journal-title":"Blood"},{"key":"5170_CR99","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/14653240802165665","volume":"10","author":"DK Hiwase","year":"2008","unstructured":"Hiwase DK, Hiwase S, Bailey M et al (2008) The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. Cytotherapy 10:507\u2013517. https:\/\/doi.org\/10.1080\/14653240802165665","journal-title":"Cytotherapy"},{"key":"5170_CR100","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/j.1537-2995.2012.03848.x","volume":"53","author":"V Varmavuo","year":"2013","unstructured":"Varmavuo V, M\u00e4ntymaa P, Silvennoinen R et al (2013) CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion (Paris) 53:1024\u20131032. https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03848.x","journal-title":"Transfusion (Paris)"},{"key":"5170_CR101","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1182\/blood.V86.1.390.bloodjournal861390","volume":"86","author":"G Schiller","year":"1995","unstructured":"Schiller G, Vescio R, Freytes C et al (1995) Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86:390\u2013397","journal-title":"Blood"},{"key":"5170_CR102","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bbmt.2018.08.020","volume":"25","author":"H Nahi","year":"2019","unstructured":"Nahi H, Celanovic M, Liu Q et al (2019) A pilot, exploratory, randomized, phase II safety study evaluating tumor cell mobilization and apheresis product contamination in patients treated with granulocyte colony-stimulating factor alone or plus plerixafor. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 25:34\u201340. https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR103","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1365-2141.2006.06054.x","volume":"133","author":"C Hosing","year":"2006","unstructured":"Hosing C, Qazilbash MH, Kebriaei P et al (2006) Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 133:533\u2013537. https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06054.x","journal-title":"Br J Haematol"},{"key":"5170_CR104","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12185-021-03177-9","volume":"114","author":"I Danylesko","year":"2021","unstructured":"Danylesko I, Sareli R, Varda-Bloom N et al (2021) Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation. Int J Hematol 114:363\u2013372. https:\/\/doi.org\/10.1007\/s12185-021-03177-9","journal-title":"Int J Hematol"},{"key":"5170_CR105","doi-asserted-by":"publisher","first-page":"590.e1","DOI":"10.1016\/j.jtct.2021.04.016","volume":"27","author":"A Johnsrud","year":"2021","unstructured":"Johnsrud A, Ladha A, Muffly L et al (2021) Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide +\/- plerixafor versus granulocyte colony-stimulating factor +\/- plerixafor in the lenalidomide era. Transplant Cell Ther 27:590.e1-590.e8. https:\/\/doi.org\/10.1016\/j.jtct.2021.04.016","journal-title":"Transplant Cell Ther"},{"key":"5170_CR106","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.bbmt.2012.01.005","volume":"18","author":"M Hamadani","year":"2012","unstructured":"Hamadani M, Kochuparambil ST, Osman S et al (2012) Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 18:1128\u20131135. https:\/\/doi.org\/10.1016\/j.bbmt.2012.01.005","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR107","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/jca.21421","volume":"31","author":"T-L Lin","year":"2016","unstructured":"Lin T-L, Wang P-N, Kuo M-C et al (2016) Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. J Clin Apheresis 31:423\u2013428. https:\/\/doi.org\/10.1002\/jca.21421","journal-title":"J Clin Apheresis"},{"key":"5170_CR108","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.bbmt.2004.02.001","volume":"10","author":"M Arora","year":"2004","unstructured":"Arora M, Burns LJ, Barker JN et al (2004) Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 10:395\u2013404. https:\/\/doi.org\/10.1016\/j.bbmt.2004.02.001","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR109","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41409-020-01053-4","volume":"56","author":"K H\u00f6lig","year":"2021","unstructured":"H\u00f6lig K, Schmidt H, H\u00fctter G et al (2021) Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial. Bone Marrow Transplant 56:635\u2013645. https:\/\/doi.org\/10.1038\/s41409-020-01053-4","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR110","doi-asserted-by":"publisher","first-page":"103052","DOI":"10.1016\/j.transci.2021.103052","volume":"60","author":"J Cid","year":"2021","unstructured":"Cid J, Monsalvo S, Castillo C et al (2021) Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: an observational case series on behalf of the Grupo Espa\u00f1ol de Trasplante Hematopoy\u00e9tico (GETH). Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 60:103052. https:\/\/doi.org\/10.1016\/j.transci.2021.103052","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"key":"5170_CR111","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/bjh.12606","volume":"164","author":"G Milone","year":"2014","unstructured":"Milone G, Martino M, Spadaro A et al (2014) Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol 164:113\u2013123. https:\/\/doi.org\/10.1111\/bjh.12606","journal-title":"Br J Haematol"},{"key":"5170_CR112","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","volume":"113","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Stadtmauer EA, Nademanee A et al (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113:5720\u20135726. https:\/\/doi.org\/10.1182\/blood-2008-08-174946","journal-title":"Blood"},{"key":"5170_CR113","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.1182\/blood-2019-130037","volume":"134","author":"TM Mark","year":"2019","unstructured":"Mark TM, Bubalo JS, Milkovich G et al (2019) A retrospective record review of mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma. Blood 134:5634. https:\/\/doi.org\/10.1182\/blood-2019-130037","journal-title":"Blood"},{"key":"5170_CR114","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3109\/10428194.2014.927454","volume":"56","author":"A Schmid","year":"2015","unstructured":"Schmid A, Friess D, Mansouri Taleghani B et al (2015) Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leuk Lymphoma 56:608\u2013614. https:\/\/doi.org\/10.3109\/10428194.2014.927454","journal-title":"Leuk Lymphoma"},{"key":"5170_CR115","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.bbmt.2007.03.007","volume":"13","author":"KK Ballen","year":"2007","unstructured":"Ballen KK, Shpall EJ, Avigan D et al (2007) Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 13:838\u2013843. https:\/\/doi.org\/10.1016\/j.bbmt.2007.03.007","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"5170_CR116","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1158\/1078-0432.CCR-12-1429","volume":"19","author":"R Niesvizky","year":"2013","unstructured":"Niesvizky R, Mark TM, Ward M et al (2013) Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clin Cancer Res Off J Am Assoc Cancer Res 19:1534\u20131546. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1429","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"5170_CR117","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1182\/blood.V116.21.824.824","volume":"116","author":"S Schmitt","year":"2010","unstructured":"Schmitt S, Weinhold N, Dembowsky K et al (2010) First results of a phase-II study with the new CXCR4 antagonist POL6326 to mobilize hematopoietic stem cells (HSC) in multiple myeloma (MM). Blood 116:824\u2013824. https:\/\/doi.org\/10.1182\/blood.V116.21.824.824","journal-title":"Blood"},{"key":"5170_CR118","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/bmt.2015.74","volume":"50","author":"N Anandasabapathy","year":"2015","unstructured":"Anandasabapathy N, Breton G, Hurley A et al (2015) Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant 50:924\u2013930. https:\/\/doi.org\/10.1038\/bmt.2015.74","journal-title":"Bone Marrow Transplant"},{"key":"5170_CR119","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood.V126.23.515.515","volume":"126","author":"G Setia","year":"2015","unstructured":"Setia G, Hagog N, Jalilizeinali B et al (2015) A phase II, open-label pilot study to evaluate the hematopoietic stem cell mobilization of TG-0054 combined with G-CSF in 12 patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin lymphoma \u2014 an interim analysis. Blood 126:515\u2013515. https:\/\/doi.org\/10.1182\/blood.V126.23.515.515","journal-title":"Blood"},{"key":"5170_CR120","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1182\/blood-2021-144296","volume":"138","author":"ZD Crees","year":"2021","unstructured":"Crees ZD, Stockerl-Goldstein KE, Larson S et al (2021) Motixafortide (BL-8040) and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma: the genesis trial. Blood 138:475. https:\/\/doi.org\/10.1182\/blood-2021-144296","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05170-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05170-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05170-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T06:06:02Z","timestamp":1681365962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05170-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":120,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["5170"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05170-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}